Table 1 Clinicopathologic characteristics of the discovery, COEUR, and CCTG OV16 cohorts.
Values (%) | ||||
|---|---|---|---|---|
Variables | Discovery | COEUR | CCTG OV16 | |
Number of patients | Total | 101 | 1158 | 267 |
Age of patients at diagnosis | Median | 61.0 | 62.0 | 56.1 |
Range | 34–81 | 26–91 | 31–76 | |
Ovarian cancer subtype | High-grade serous | 101 (100.0) | 1093 (94.4) | 267 (100.0) |
Low-grade serous | / | 31 (2.7) | / | |
Endometrioid | / | 14 (1.2) | / | |
Clear cell | / | 9 (0.8) | / | |
Mucinous | / | 2 (0.2) | / | |
Unknown | / | 9 (0.8) | / | |
Stage (FIGO) | I | 4 (4.0) | 77 (6.7) | / |
II | 7 (6.9) | 124 (10.7) | 28 (10.5) | |
III | 72 (71.3) | 801 (69.2) | 173 (64.8) | |
IV | 12 (11.9) | 108 (9.30) | 66 (24.7) | |
Unknown | 6 (5.9) | 48 (4.10) | / | |
Residual disease | No residual disease | 18 (17.8) | 206 (17.8) | 47 (17.6) |
Yes, size not specified | 7 (6.9) | 155 (13.4) | / | |
≤1 cm | 20 (19.8) | 224 (19.3) | 70 (26.2) | |
1–≤2 cm | 22 (21.8) | 81 (7.0) | 114 (42.7) | |
>2 cm | 26 (25.7) | 171 (14.8) | / | |
Miliary | 3 (3.0) | 34 (2.9) | / | |
No debulking surgery | / | / | 31 (11.6) | |
Unknown | 5 (5.0) | 287 (24.8) | 5 (1.9) | |
Chemotherapy before surgery | No | 98 (97.0) | 1093 (94.4) | 267 (100.0) |
Yes | 3 (3.0) | 65 (5.6) | / | |
Unknown | / | / | / | |
Chemotherapy type | Platinuma + taxol | 76 (75.2) | 901 (77.8) | 139 (52.1) |
Platinuma | 2 (2.0) | 59 (5.1) | / | |
Taxol | 2 (2.0) | 3 (0.3) | / | |
Others | 21 (20.8) | 98 (8.5) | 128 (47.9)b | |
None | / | 22 (1.9) | / | |
Unknown | / | 75 (6.5) | / | |
BRCA1/2 status | Wild-type | / | 339 (29.3) | / |
BRCA1 mutation | / | 53 (4.5) | / | |
BRCA2 mutation | / | 22 (1.9) | / | |
BRCA1/2 mutationsc | / | 3 (0.3) | / | |
Unknown | / | 741 (64.0) | / | |
Menopausal status | No | 17 (16.8) | / | / |
Yes | 51 (50.5) | / | / | |
Unknown | 33 (32.7) | / | / | |
Age of FFPE blocks | Median (years from study) | 15.0 | 10.0 | 14.5 |
Range (years from study) | 6–25 | 3–25 | 12.4–16.5 | |
Overall survival status | Alive | 24 (23.7) | 464 (40.1) | 61 (22.8) |
Deceased | 72 (71.3) | 647 (55.9) | 206 (77.2) | |
Unknown | 5 (5.0) | 47 (4.0) | / | |
Overall survival time (months) | Median (months) | 48.0 | 36.1 | 45.1 |
Range (months) | 3–202 | 0–202 | 0.8–127.1 | |
Progression-free survival status | No progression | 19 (18.8) | 256 (22.1) | 30 (11.2) |
Progression | 81 (80.2) | 817 (70.6) | 237 (88.8) | |
Unknown | 1 (1.0) | 85 (7.3) | / | |
Progression-free survival time (months) | Median (months) | 18.0 | 15.0 | 16.3 |
Range (months) | 1–202 | 0–195 | 0.8–126.0 | |
